FRAXIPARINE FORTE SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

NADROPARIN CALCIUM

제공처:

ASPEN PHARMACARE CANADA INC.

ATC 코드:

B01AB06

INN (국제 이름):

NADROPARIN

복용량:

19000UNIT

약제 형태:

SOLUTION

구성:

NADROPARIN CALCIUM 19000UNIT

관리 경로:

INTRAVENOUS

패키지 단위:

0.6ML

처방전 유형:

Prescription

치료 영역:

HEPARINS

제품 요약:

Active ingredient group (AIG) number: 0131662002; AHFS:

승인 상태:

APPROVED

승인 날짜:

2015-04-20

제품 특성 요약

_Pr_
_FRAXIPARINE_
_® _
_& _
_Pr_
_FRAXIPARINE_
_®_
_ FORTE (_nadroparin calcium injection_) _
_Page 1 of 50_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
FRAXIPARINE
®
nadroparin calcium injection (9,500 anti-Xa IU/mL)
0.2 mL, 0.3 mL, 0.4 mL, 0.6 mL and 1.0 mL prefilled syringes
PR
FRAXIPARINE
® FORTE
nadroparin calcium injection (19,000 anti-Xa IU/mL)
0.6 mL, 0.8 mL and 1.0 mL prefilled syringes
Manufactures Standard
Topical Anesthetic for Dermal Analgesia
Aspen Pharmacare Canada Inc
8 – 1155 North Service Road West
Oakville, ON
L6M 3E3
Date of Initial Approval:
February 05, 1998
Date of Revision:
July 8, 2022
Submission Control Number: 260986
Trademarks are owned by or licensed to the Aspen Group of companies.
_Product Monograph Master Template _
_Template Date: September 2020 _
_Pr_
_FRAXIPARINE_
_® _
_& _
_Pr_
_FRAXIPARINE_
_®_
_ FORTE (_
nadroparin calcium injection
_) _
_Page 2 of 50_
RECENT MAJOR LABEL CHANGES
1 Indications
(Removed) 06/2016
1 Indications, 1.2 Geriatrics
(Removed) 06/2016
4 Dosage and Administration, 4.2 Recommended Dose and Dosage
Adjustment
(Removed) 09/2017
Patient Medication Information
(Removed) 09/2017
11 Storage, Stability and Disposal
(Removed) 02/2018
7 Warnings and Precautions
09/2021
TABLE OF CONTENTS
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1
INDICATIONS
................................................................................................................4
1.1
Pediatrics (<18 years of age):
...............................................................................4
1.2
Geriatrics (≥ 65 years of age):
...............................................................................4
2
CONTRAINDICATIONS
................